BioMarin Pharmaceutical Inc. (BMRN) Earnings History
Annual and quarterly earnings data from 1998 to 2025
Loading earnings history...
BMRN EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
BMRN Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 77.1% | 16.6% | 10.8% |
| 2024 | 79.7% | 17.0% | 15.0% |
| 2023 | 78.0% | 7.7% | 6.9% |
| 2022 | 76.0% | 7.7% | 6.8% |
| 2021 | 74.5% | -4.5% | -3.5% |
Download Data
Export BMRN earnings history in CSV or JSON format
Free sign-in required to download data
BioMarin Pharmaceutical Inc. (BMRN) Earnings Overview
As of May 7, 2026, BioMarin Pharmaceutical Inc. (BMRN) reported trailing twelve-month net income of $269M, reflecting -18.6% year-over-year growth. The company earned $1.36 per diluted share over the past four quarters, with a net profit margin of 10.8%.
Looking at the long-term picture, BMRN's 5-year EPS compound annual growth rate (CAGR) stands at -16.9%, signaling declining earnings. The company achieved its highest annual net income of $854M in fiscal 2020.
BioMarin Pharmaceutical Inc. maintains positive profitability with a gross margin of 77.1%, operating margin of 16.6%, and net margin of 10.8%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including RARE (-$609M net income, -85.4% margin), SRPT ($65M net income, -32.5% margin), IONS (-$327M net income, -40.4% margin), BMRN has outperformed on profitability metrics. Compare BMRN vs RARE →
BMRN Earnings vs Peers
Earnings metrics vs comparable public companies
BMRN Historical Earnings Data (1998–2025)
28 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $349M | -18.3% | $533M | $1.80 | 10.8% | 16.6% |
| 2024 | $427M | +154.6% | $484M | $2.21 | 15.0% | 17.0% |
| 2023 | $168M | +18.4% | $186M | $0.88 | 6.9% | 7.7% |
| 2022 | $142M | +320.9% | $161M | $0.75 | 6.8% | 7.7% |
| 2021 | -$64M | -107.5% | -$82M | $-0.35 | -3.5% | -4.5% |
| 2020 | $854M | +3681.1% | -$43M | $4.53 | 45.9% | -2.3% |
| 2019 | -$24M | +69.1% | -$100M | $-0.13 | -1.4% | -5.9% |
| 2018 | -$77M | +34.0% | -$124M | $-0.44 | -5.2% | -8.3% |
| 2017 | -$117M | +81.4% | -$15M | $-0.67 | -8.9% | -1.1% |
| 2016 | -$630M | -266.8% | -$803M | $-3.79 | -56.4% | -71.9% |
Full BMRN Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See BMRN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BMRN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BMRN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBMRN — Frequently Asked Questions
Quick answers to the most common questions about buying BMRN stock.
Is BMRN growing earnings?
BMRN EPS fell to $1.36, with earnings declining -18.6%. This contrasts with the 5-year CAGR of -16.9%. TTM net income dropped to $269M.
What are BMRN's profit margins?
BioMarin Pharmaceutical Inc. net margin is +10.8%, with operating margin at +16.6%. Margins sit within typical range for the sector.
How consistent are BMRN's earnings?
BMRN earnings data spans 1998-2025. The declining earnings trend is -18.6% YoY. Historical data enables comparison across business cycles.